The main goal of this Myelonna SPORE program is to develop novel targeted therapies to more effectively treat patients with multiple myeloma (MM). Clinically relevant animal models are crucial for examining the in vivo efficacy of novel agents. The dedicated personnel and facilities of the Animal Models Core (Core D) provide the program with clinically relevant animal models and expertise in animal studies essential to achieving the aims ofthe Projects. Core personnel work closely with SPORE investigators to plan animal studies and to develop optimal and clinically relevant mouse models of myeloma. During the past 5 years, the Department of Lymphoma and Myeloma and M. D. Anderson Cancer Center have provided excellent conditions in terms of access to primary myeloma samples, myeloma tissue bank, interaction between clinical and translational research programs, and animal facilities for providing unique, clinically relevant samples to establish myeloma SCID and SCID-hu mouse models, which allow reproducibly engraftment of established human myeloma cell lines or primary myeloma cells freshly isolated from patients with MM, respectively. Establishment of myeloma in SCID-hu mice induces typical human MM manifestations including disease heterogeneity commonly seen in the clinic. The Animal Models Core is well suited to provide expertise and mouse models for the SPORE given that the Animal Models Core Personnel, animal facilities, and tissue banks are all located within the South Campus Research Buildings of our institution where our laboratories are concentrated. This provides a level of integration for the Core that will maximize uniformity and use of available animal models and patients'materials by SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-03
Application #
8380826
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2012
Total Cost
$72,775
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397
Davenport, Clemontina A; Maity, Arnab; Baladandayuthapani, Veerabhadran (2018) Functional interaction-based nonlinear models with application to multiplatform genomics data. Stat Med 37:2715-2733
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239
Thomas, Sheeba K; Cha, Soung-Chul; Smith, D Lynne et al. (2018) Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18:187
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Ok, Chi Young; Young, Ken H (2017) Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99-109
Lee, Hans C; Wang, Hua; Baladandayuthapani, Veerabhadran et al. (2017) RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177:80-94

Showing the most recent 10 out of 203 publications